A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Clinical trial NCT05498428 · RECRUITING

Trial details

NCT number: NCT05498428
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-small-Cell Lung

Start date: 2022-11-11
Primary completion: 2027-08-17
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.